6533b820fe1ef96bd1279c2a
RESEARCH PRODUCT
A combined approach for gene discovery identifies insulin-like growth factor-binding protein-related protein 1 as a new gene implicated in human endometrial receptivity.
Carlos SimónAna CerveroJosé Luis CastrilloFrancisco DomínguezJulio MartínSilvia AvilaAntonio Pellicersubject
Endocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryBiologyEndometriumBiochemistryInsulin-like growth factor-binding proteinCell LineEndometriumMiceEndocrinologyPregnancyGene expressionmedicineCell AdhesionAnimalsHumansRNA MessengerReceptorGeneIn Situ HybridizationMenstrual CycleFluorescent DyesMessenger RNAReverse Transcriptase Polymerase Chain ReactionBiochemistry (medical)Epithelial CellsMolecular biologyImmunohistochemistryInsulin-Like Growth Factor Binding ProteinsCytokinemedicine.anatomical_structureBlastocystGene Expression RegulationCell culturebiology.proteinFemaleStromal CellsCarrier Proteinsdescription
In the past, human endometrial receptivity has been investigated by chasing specific molecules throughout the menstrual cycle. Now the genomic approach allows us to investigate the hierarchical contribution of a high number of genes to a specific function. In this study, we analyzed differentially the gene expression pattern of 375 human cytokines, chemokines, and related factors, plus that of their receptors, in endometrial receptivity. To do this, we used a combined approach of human endometrium and cell lines. We have compared the gene expression pattern in receptive vs. prereceptive human endometria and contrasted the results with gene expression in the highly adhesive cell line (to JAR cells and mouse blastocysts) RL95-2 vs. HEC-1A, a cell line with markedly less adhesiveness. IGF-binding protein-related protein 1 (IGFBP-rP1), also known as IGFBP-7/mac 25, was the second most up-regulated gene in both of the investigated models. These results were corroborated by performing RT-PCR on the same RNA samples and validated by quantitative fluorescent RT-PCR and in situ hybridization in endometrium throughout the menstrual cycle. Interestingly, a 35-fold increase in expression during the receptive phase was compared with the prereceptive phase followed by a sharp increase in the late luteal. Further quantitative fluorescent RT-PCR experiments using the epithelial and stromal endometrial fraction throughout the menstrual cycle confirmed that IGFBP-rP1 expression was localized in the epithelial and stromal compartments and up-regulated mainly in the latter. In situ experiments confirmed the endometrial localization and regulation of IGFBP-rP1 mRNA. At the protein level, IGFBP-rP1 was localized by immunohistochemistry at the apical part of the luminal and glandular epithelium, stromal, and endothelial cells. In conclusion, using a genomic approach with a combined experimental design of receptivity in vivo and in vitro, we have discovered the implication of IGFBP-rP1 in endometrial physiology, which seems related to endometrial receptivity.
year | journal | country | edition | language |
---|---|---|---|---|
2003-04-01 | The Journal of clinical endocrinology and metabolism |